TCA Cycle in the Dentate in Friedreich's Ataxia

Status Completed

Clinical Trial Summary

OBJECTIVE: To measure the tricarboxylic acid (TCA) cycle rate in the dentate nucleus in a group of control subjects and subjects with Friedreich's Ataxia (FRDA). HYPOTHESIS: The TCA cycle rate will be lower in FRDA subjects than in controls APPROACH: The investigators will infuse carbon-13 (13C) labeled glucose and measure the rate of 13C label incorporation from glucose to glutamate in the brain using in vivo magnetic resonance spectroscopy.

Clinical Trial Description

The investigators will measure the TCA cycle rate in the dentate nucleus in a group of FRDA patients and in a group of age-matched healthy controls using 13C MRS in vivo together with systemic i.v. infusion of 13C-labeled glucose. The investigators aim to obtain adequate data in 16 subjects grouped as follows: - n=4 pilot subjects (healthy subjects) for testing and optimization of the experimental setup. - n=6 healthy controls - n=6 FRDA patients In other to reach this goal, the investigators plan to recruit up to 20 subjects, in case some subjects withdraw before completion of the MR scan, or in case the measured data are not adequate (e.g. technical problem with the scanner). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03122925
Study type	Observational
Source	University of Minnesota
Contact
Status	Completed
Phase
Start date	August 29, 2017
Completion date	January 11, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05573698` - Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia	Phase 1
Completed	`NCT00229632` - Idebenone to Treat Friedreich's Ataxia	Phase 2
Completed	`NCT05579691` - A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia	Phase 2
Completed	`NCT04273165` - Safety and Efficacy of Etravirine in Friedreich Ataxia Patients	Phase 2
Not yet recruiting	`NCT05874388` - Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia	N/A
Completed	`NCT02594917` - Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
Completed	`NCT01716221` - An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia	Phase 4
Active, not recruiting	`NCT05485987` - A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia	Phase 2
Completed	`NCT03214588` - Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia	Phase 2
Completed	`NCT03418740` - Neurology Measures in FA Children
Not yet recruiting	`NCT06054893` - A Study of Omaveloxolone in Children With Friedreich's Ataxia	Phase 1
Recruiting	`NCT04921930` - Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)	Phase 1/Phase 2
Completed	`NCT03933163` - Micronised Resveratrol as a Treatment for Friedreich Ataxia	Phase 2
Completed	`NCT02705547` - Rosuvastatin (Crestor) in Friedreich Ataxia	Early Phase 1
Completed	`NCT02035020` - A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients	Phase 2
Completed	`NCT00015808` - Safety Study of Idebenone to Treat Friedreich's Ataxia	Phase 1
Completed	`NCT04817111` - NAD+ Precursor Supplementation in Friedreich's Ataxia	Phase 2
Active, not recruiting	`NCT05168774` - FRDA Investigator Initiated Study (IIS) With Elamipretide	Phase 1/Phase 2
Completed	`NCT03917225` - A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients	Phase 2
Completed	`NCT00224640` - Iron-Chelating Therapy and Friedreich Ataxia	Phase 1/Phase 2